Product logins

Find logins to all Clarivate products below.


Asthma (Positioning of Current and Emerging Agents) | Physician & Payer Forum | Brazil and Mexico | 2014

Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) fixed-dose combination (FDC) Relvar/Relvare (GlaxoSmithKline/Theravance’s vilanterol/fluticasone furoate) and the anticipated label extension of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer’s tiotropium) for asthma are likely to drive market growth. Furthermore, Cinquil (Cephalon/Teva’s reslizumab) and Bosatria (GlaxoSmithKline’s mepolizumab), interleukin-5 (IL-5)-targeting biologics in late-stage development, will add a competitive dynamic to the severe, disease-refractory market segment, which represents a patient population characterized by high morbidity and frequent hospitalizations for whom Xolair (Genentech/Novartis’s omalizumab) is currently the only therapeutic option. Severe, refractory asthma is undoubtedly a burden to the healthcare systems in the countries under study, but it equally represents remaining therapeutic need and therefore ample opportunity for developers. However, the rising cost of the asthma treatment armamentarium will be balanced by increasing coverage restrictions; drug makers must carefully navigate the road to reimbursement in order to optimize uptake.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
Report
Asthma | Disease Landscape & Forecast | G7 | 2024
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…